Pedro Cruz

6PUBLICATIONS
28CO-AUTHORS
Oncology and carcinogenesis not elsewhere classifiedMolecular targetsInnate immunityPredictive and prognostic markersElectronic and magnetic properties of condensed matter; superconductivity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 28, 2026
Correction: Cruz et al. Drug Development in Non-Oncogene-Addicted Non-Small Cell Lung Cancer. Cancers 2026, 18, 880.

|Mar 14, 2026
Drug Development in Non-Oncogene-Addicted Non-Small Cell Lung Cancer.

Pedro Cruz, Cristina Boixareu, Diogo J Silva

|Jan 24, 2025
Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving Pathogens.

Pedro Cruz, Jie Min Lam, Jehad Abdalla

|Nov 26, 2024
Humoral Response to SARS-CoV-2 Vaccine-Boost in Cancer Patients: A Case Series from a Southern European Cancer Center.

Júlio Oliveira, Pedro Cruz, Tânia R Dias

|Aug 29, 2024
Plasma EV-miRNAs as Potential Biomarkers of COVID-19 Vaccine Immune Response in Cancer Patients.

Beatriz Almeida, Tânia R Dias, Pedro Cruz

|Oct 24, 2020
Myocardial infarction affects Cx43 content of extracellular vesicles secreted by cardiomyocytes.

Tania Martins-Marques, Teresa Ribeiro-Rodrigues, Saskia C de Jager

Pageof 1

Frequent Collaborators

2 joint publications

Joshua Ting

2 joint publications

Anna Minchom

2 joint publications

Steph A Pang

2 joint publications

Rayssa Sena